LevelJump Healthcare Corp. Reports Third Quarter 2023 Results
LevelJump Healthcare Corp. Reports Third Quarter 2023 Results
Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30, 2023. All amounts are expressed in Canadian dollars.
加拿大安大略省多伦多--(Newsfile Corp.,2023年11月29日)——加拿大B2B远程医疗解决方案领域的领导者LevelJump Healthcare Corp.(多伦多证券交易所股票代码:JUMP)(场外交易代码:JMPHF)(FSE:75J)(“LevelJump” 或 “公司”)今天欣然宣布,它已公布截至2023年9月30日的第三财季的财务业绩。所有金额均以加元表示。
Financial and Operational Highlights
财务和运营要点
Revenues from operations were $2,856,044 for the third quarter, an increase of 31% from the prior year.
Gross profits from operations were $739,479 for the third quarter, an increase of 14% from the prior year.
第三季度的运营收入为2856,044美元,比上年增长31%。
第三季度的运营总利润为739,479美元,比上年增长14%。
"Despite a challenging market and economic landscape, we progressed on our organic growth and our acquisition plan as well as expanded our teleradiology services to Saskatchewan, solidifying JUMP as a national provider," said Mitch Geisler, CEO. "Looking ahead, our immediate priority is to sustain revenue growth by leveraging both our recently acquired and established Diagnostic Centers while consistently delivering value to our shareholders."
首席执行官米奇·盖斯勒说:“尽管市场和经济格局充满挑战,但我们在有机增长和收购计划方面取得了进展,并将远程放射学服务扩展到了萨斯喀彻温省,巩固了JUMP作为全国提供商的地位。”“展望未来,我们的当务之急是通过利用我们最近收购和建立的诊断中心来维持收入增长,同时持续为股东创造价值。”
Non-IFRS Financial Measures
非国际财务报告准则财务指标
This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.
本新闻稿包含国际财务报告准则中未考虑的财务条款(例如调整后的息税折旧摊销前利润)。此类财务指标加上根据国际财务报告准则制定的衡量标准,为投资者和股东提供了有用的信息,因为管理层使用它们来评估公司的经营业绩。公司对这些非国际财务报告准则指标的确定可能与其他申报发行人不同,因此不太可能与其他公司提出的类似指标相提并论。此外,不应孤立地考虑这些非《国际财务报告准则》衡量标准,也不能替代按照《国际财务报告准则》编制的业绩或现金流衡量标准。之所以包括这些财务指标,是因为管理层使用这些信息来分析经营业绩和流动性。
Adjusted EBITDA & Annual Revenue Run Rate
调整后的息税折旧摊销前利润和年收入运行率
Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.
管理层认为,调整后的息税折旧摊销前利润是确定公司为营运资金、资本支出、债务偿还、利息支出和所得税产生可用现金的有用补充衡量标准。
EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income), income tax expense (recovery) and extraordinary items. The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment, and finance income.
息税折旧摊销前利润是指根据国际财务报告准则确定的折旧和摊销前的净收益(亏损)、净利息支出(收入)、所得税支出(回收)和特殊项目。公司将调整后的息税折旧摊销前利润定义为息税折旧摊销前利润,加上股票薪酬支出、重组、公允价值调整、上市费用和交易成本、减值和财务收益。
A reconciliation of adjusted EBITDA to net income (loss) is as follows.
调整后的息税折旧摊销前利润与净收益(亏损)的对账情况如下。
3 Months ended September 30, 2023 |
3 Months ended September 30, 2022 |
9 Months ended September 30, 2023 |
9 Months ended September 30, 2023 |
|||||||||
|
||||||||||||
Revenues | 2,856,044 | 2,296,187 | 9,015,126 | 6,611,990 | ||||||||
Cost of Sales | 2,116,565 |
1,649,041 |
6,400,165 |
4,818,527 | ||||||||
Gross Profit | 739,479 |
647,146 |
2,614,962 |
1,793,463 | ||||||||
Operating Expenses | 947,065 | 813,637 | 3,180,811 | 2,499,092 | ||||||||
Net Profit | (207,586) | (166,491) | (565,850) | (705,629) | ||||||||
Other Income | - | 188 | 116,604 | 102,958 | ||||||||
Other Expenses | 1,386,054 |
43,315 |
1,579,627 |
134,545 | ||||||||
Net Income/(Loss) | (1,593,641) | (209,618) | (2,028,873) | (737,216) | ||||||||
add back | ||||||||||||
Finance costs | 59,411 | 40,219 | 176,587 | 100,358 | ||||||||
Amortization and Depreciation | 129,059 |
51,335 |
341,251 |
145,368 | ||||||||
EBITDA | (1,405,171) | (118,064) | (1,511,034) | (491,490) | ||||||||
add back | ||||||||||||
Stock Based compensation | - | 36,833 | - | 256,499 | ||||||||
Broker Commissions | - | - | 66,500 | 20,201 | ||||||||
Investment losses | 1,329,876 | - | 1,329,876 | 2,971 | ||||||||
Other | (3,232) | 3,096 | 6,664 | 11,015 | ||||||||
One time nonrecurring operating expenses | 100,000 | 100,000 | 100,000 | 100,000 | ||||||||
subtract other Income | - |
188 |
116,604 |
102,958 | ||||||||
Adjusted EBITDA | 21,473 |
21,677 |
(124,598) | (203,762) |
3 个月已结束 2023年9月30日 |
3 个月已结束 2022年9月30日 |
9 个月已结束 2023年9月30日 |
9 个月已结束 2023年9月30日 |
|||||||||
|
||||||||||||
收入 | 2,856,044 | 2,296,187 | 9,015,126 | 6,611,990 | ||||||||
销售成本 | 2,116,565 |
1,649,041 |
6,400,165 |
4,818,527 | ||||||||
毛利 | 739,479 |
647,146 |
2,614,962 |
1,793,463 | ||||||||
运营费用 | 947,065 | 813,637 | 3,180,811 | 2,499,092 | ||||||||
净利润 | (207,586) | (166,491) | (565,850) | (705,629) | ||||||||
其他收入 | - | 188 | 116,604 | 102,958 | ||||||||
其他开支 | 1,386,054 |
43,315 |
1,579,627 |
134,545 | ||||||||
净收益/(亏损) | (1,593,641) | (209,618) | (2,028,873) | (737,216) | ||||||||
再加回来 | ||||||||||||
财务成本 | 59,411 | 40,219 | 176,587 | 100,358 | ||||||||
摊销和折旧 | 129,059 |
51,335 |
341,251 |
145,368 | ||||||||
EBITDA | (1,405,171) | (118,064) | (1,511,034) | (491,490) | ||||||||
再加回来 | ||||||||||||
股票薪酬 | - | 36,833 | - | 256,499 | ||||||||
经纪人佣金 | - | - | 66,500 | 20,201 | ||||||||
投资损失 | 1,329,876 | - | 1,329,876 | 2,971 | ||||||||
其他 | (3,232) | 3,096 | 6,664 | 11,015 | ||||||||
一次性非经常性运营费用 | 10万 | 10万 | 10万 | 10万 | ||||||||
减去其他收入 | - |
188 |
116,604 |
102,958 | ||||||||
调整后 EBITDA | 21,473 |
21,677 |
(124,598) | (203,762) |
About LevelJump Healthcare
关于 LevelJump
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
LevelJump Healthcare Corp.(多伦多证券交易所股票代码:JUMP)通过其远程放射学部门为客户医院和成像中心提供远程医疗解决方案,并通过其IHF(独立医疗机构)提供面对面放射学服务。JUMP主要专注于紧急和急诊患者的重症监护,在我们所服务的社区中建立不可或缺的关系。
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
代表董事会
LEVELJUMP 医疗保健公司
Mitchell Geisler
Chief Executive Officer
米切尔·盖斯勒
首席执行官
Caitlin-Robyn Densmore
Investor Relations Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568
Caitlin-Robyn Densmore
投资者关系经理
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
关于前瞻性信息的警示声明
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
本新闻稿包含与公司业务计划和公司行业前景有关的适用证券法所指的 “前瞻性信息”。尽管根据其高管和董事的经验、当前状况和预期的未来发展以及其他被认为适当的因素,公司认为,这些前瞻性信息中反映的预期是合理的,但不应过度依赖这些期望,因为公司无法保证这些预期会被证明是正确的。实际结果和发展可能与这些陈述所设想的结果和进展存在重大差异。本新闻稿中的声明自本新闻稿发布之日起作出,除适用的证券法要求外,公司不承担任何责任对其进行更新或修改以反映新的事件或情况。公司没有义务评论第三方对公司、Canadian Teleradiology Services, Inc.、其证券或各自的财务或经营业绩(如适用)的分析、预期或声明。
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
交易所及其监管服务提供商(该术语在联交所政策中定义)均不对本新闻稿的充分性或准确性承担责任。
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
所发行的证券过去和将来都没有根据经修订的1933年《美国证券法》(“美国证券法”)或任何美国州证券法进行注册,也不得在美国发行或出售,也不得向未经注册或适用《美国证券法》和适用的美国州证券法注册要求豁免的美国人发行或出售,也不得为美国人的账户或利益进行发行或出售。本新闻稿不构成在美国或任何其他司法管辖区出售证券的要约或要求购买证券的要约。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问